This is where a new study on one CDK7 inhibitor, SY-5609, may offer a breakthrough, indicating the CDK7 is not doing its damage in what was considered the most likely way. Professor Dylan Taatjes ...

New CU Boulder research, published in the journal Science Advances, offers unprecedented insight into how an enigmatic enzyme, known as CDK7, drives this complex process. The research shows that ...

The initial programs target CDK7/9, GSPT1, CK1a, IKAROS, PDE4, and KRAS with the potential to address a broad range of therapeutic areas including oncology, inflammation and other diseases.

New CU Boulder research, published in the journal Science Advances, offers unprecedented insight into how an enigmatic enzyme, known as CDK7, drives this complex process. The research shows that ...